Argenx Takes an Unusual Phase 3 Hit in Sjögren’s Disease
Argenx opened the week with an unexpected miss. Vyvgart, the company’s flagship autoimmune drug, failed to beat placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder marked by systemic immune dysfunction and a notoriously variable symptom burden. The study stopped early after a data monitoring committee concluded the primary endpoint would not be met.
The result matters because Argenx has built a reputation on a run of wins across autoimmune disease. That track record had made the company look unusually durable in a therapeutic class where many programs stumble on heterogeneous biology, modest effect sizes, and clinical endpoints that can be hard to move. Sjögren’s disease is a particularly unforgiving proving ground: symptoms can fluctuate, placebo responses can run high, and patient-reported outcomes often blur the line between true drug effect and the noise of chronic illness.
William Blair analysts had projected $1.4 billion in peak sales for Vyvgart in Sjögren’s disease, while also calling the study high risk. Their caution reflected the core challenge in the indication. When placebo responses are strong, a therapy must produce a clear and sustained biological effect to separate itself from the background variability that can accompany fatigue, dryness, pain, and systemic complaints. A drug that succeeds in one autoimmune setting cannot assume the same path in another, because the immune pathways driving disease activity may overlap only partially.
The early stop also changes the commercial conversation around Argenx’s broader autoimmune ambitions. A failure in a major indication does not erase the drug’s existing profile, but it does remind investors and clinicians that mechanism alone does not guarantee translation. In practice, phase 3 failure in Sjögren’s disease suggests either insufficient target engagement in this population, an endpoint that was too vulnerable to placebo effects, or both. For a disorder with diffuse symptoms and limited objective markers, even a biologically plausible therapy can fall short when the readout depends on outcomes that patients and investigators experience unevenly.
FDA Scrutiny Intensifies Around Investigational Evenamide
Across the anti-psychotic development space, the Food and Drug Administration has raised a separate concern: a potential safety signal after four deaths were reported among patients with treatment-resistant schizophrenia who received investigational evenamide in clinical trials. Newron Pharmaceuticals had already faced an enrollment halt in April after the sudden death of a participant in a Phase 3 study. That hold remains in place at U.S. study centers.
Enrollment continues outside the United States, and additional clinical sites are being added. Even so, the regulatory posture is clear. The agency is worried about a class-specific problem tied to sodium channel blockers, which can trigger arrhythmias and, in some settings, contribute to serious cardiovascular events or seizures. In a population already exposed to substantial illness burden and polypharmacy, the threshold for safety concern is understandably low.
Treatment-resistant schizophrenia leaves few therapeutic options, which is exactly why investigational agents move through development despite unresolved safety questions. Yet any signal involving unexplained deaths forces a different calculus. A molecule that modulates sodium channels may offer theoretical benefit in neuropsychiatric disease, but the same pharmacology can affect cardiac conduction. When death occurs during development, especially across multiple participants, regulators and investigators must determine whether the association is coincidental or mechanistically credible. The difference is practical, not theoretical.
For clinicians following the field, the episode is a reminder that psychiatric drug development often depends on a narrow margin between efficacy and harm. Patients with refractory psychosis may be more willing to accept risk, but trial oversight does not bend to desperation. The presence of a safety hold in one country while enrollment continues elsewhere also exposes the uneven geography of development: global studies can keep moving even as one regulator demands answers. Any eventual readout will have to confront both the efficacy question and the cardiovascular question at the same time.
What These Two Developments Say About Drug Development Risk
The juxtaposition is hard to miss. On one side sits a blockbuster autoimmune therapy that missed in a disease with a difficult placebo profile. On the other stands an experimental schizophrenia treatment under regulatory pressure after multiple deaths were reported in trials. Both stories point to the same structural reality in medicine: late-stage development can fail because the biology is too complex, the endpoint too noisy, or the safety margin too narrow.
In Sjögren’s disease, the challenge is efficacy signal extraction. In treatment-resistant schizophrenia, it is safety signal detection. One program is likely to be judged by whether it can do better than a powerful placebo response; the other by whether it can survive scrutiny around fatal adverse events that may be linked to its mechanism. In both cases, the data monitoring process is not a formality. It is the point at which clinical promise collides with human variability.
For Argenx, the setback will force a reassessment of how much optionality remains in Sjögren’s disease and whether the drug’s autoimmune franchise can expand without this indication. For Newron, the central issue is whether evenamide can clear the regulator’s concerns without losing momentum outside the U.S. and whether ongoing studies can generate enough safety clarity to justify continued investment. Neither story offers a clean conclusion yet. Both do offer a reminder that late-stage pharmacology is rarely decided by optimism alone.